[Long-term treatment of spasticity with tisanidine (sirdulad) in 2 cases of multiple sclerosis]

[Article in Polish]

Case Reports

[Article in Polish]

W Cendrowski. Wiad Lek. 1987.

. 1987 Dec 15;40(24):1711-4.

No abstract available

Similar articles

A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
Smolenski C, Muff S, Smolenski-Kautz S. Smolenski C, et al. Curr Med Res Opin. 1981;7(6):374-83. Curr Med Res Opin. 1981. PMID: 7016449 Clinical Trial.
[Long-term treatment with an imidazoline derivative (DS 103--282) (author's transl)].
Gerstenbrand F, Lorincz A, Ludin HP, Ringwald E. Gerstenbrand F, et al. Nervenarzt. 1979 Dec;50(12):806-8. Nervenarzt. 1979. PMID: 547191 German. No abstract available.
A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
[No authors listed] [No authors listed] Neurology. 1994 Nov;44(11 Suppl 9):S70-8. Neurology. 1994. PMID: 7970014 Clinical Trial.
An approach to switching patients from baclofen to tizanidine.
Brenner R, Hyman N, Knobler R, O'Brien M, Stephan T. Brenner R, et al. Hosp Med. 1998 Oct;59(10):778-82. Hosp Med. 1998. PMID: 9850294 Review.
Drug treatment of multiple sclerosis.
Rudick RA, Schiffer RB, Herndon RM. Rudick RA, et al. Semin Neurol. 1987 Jun;7(2):150-9. doi: 10.1055/s-2008-1041415. Semin Neurol. 1987. PMID: 2845549 Review. No abstract available.